Delving into the Latest Updates on ViiV Healthcare Co. with Synapse

Overview

Tags

Infectious Diseases

Immune System Diseases

Urogenital Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	13
Infectious Diseases	13
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	13

Top 5 Target	Count

HIV integrase	4
RT(Viral reverse transcriptase)	4
HIV integrase x RT	3
CCR5(C-C chemokine receptor type 5)	1
HIV envelope protein gp120	1

Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention, learning, and working memory in 293 HIV-1-infected, ART-experienced, and virologically suppressed adults. The ASSURE study randomized participants 1:2 to remain on tenofovir/emtricitabine (TDF/FTC) and ritonavir-boosted atazanavir (ATV/r) or simplify to abacavir/lamivudine + atazanavir (ABC/3TC + ATV). Neurocognitive z-scores were computed using demographically adjusted normative data and were classified as "impaired" (defined as either a z-score ≤ - 2 or having 2 or more standardized individual test z-scores ≤ - 1); while higher scores (equaling better performance) were classified as "normal". By z-scores, 54.7% of participants had impaired neurocognition at baseline and 50.2% at week 48. There were no significant differences (p < 0.05) in the baseline-adjusted performance between treatment groups for any individual test or by z-score. Specific demographic and medical risk factors were evaluated by univariate analysis for impact on neurocognitive performance. Factors with p < 0.10 were evaluated by backwards regression analysis to identify neurocognition-correlated factors after accounting for treatment, assessment, and baseline. Four risk factors at baseline for impaired neurocognition were initially identified: lower CD4 nadir lymphocyte counts, higher Framingham risk scores, and interleukin-6 levels, and a history of psychiatric disorder not otherwise specified, however none were found to moderate the effect of treatment on neurocognition. In this aviremic, treatment-experienced population, baseline-adjusted neurocognitive function remained stable and equivalent over 48 weeks with both TDF/FTC + ATV/r-treated and in the ART-simplified ABC/3TC + ATV treatment groups.

100 Deals associated with ViiV Healthcare Co.

Login to view more data

100 Translational Medicine associated with ViiV Healthcare Co.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

11

Approved

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Dolutegravir Sodium ( HIV integrase )	HIV Infections More	Approved
Cabotegravir sodium ( HIV integrase )	HIV Infections More	Approved
Dolutegravir Sodium/Lamivudine ( HIV integrase x RT )	HIV Infections More	Approved
Cabotegravir/Rilpivirine ( HIV integrase x RT )	HIV Infections More	Approved
Zidovudine ( RT )	HIV Infections More	Approved